Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115383) titled 'Real-World Study of Ustekinumab in the Treatment of Plaque Psoriasis in Chinese Population Aged 6 Years and Above' on Dec. 25, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: The Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition:
Plaque Psoriasis
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: Ustekinumab Group:1100;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302204
Disclaimer: Curated by HT Syndication....